Qué está moviendo el mercado.

Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet

Stock Preachers News Commentary NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Stocks closed out a choppy week on the back foot, with the Dow shedding nearly 2% and small caps underperforming as the Russell 2000 fell more than 1% on the week. The…

RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

RedHill Biopharma Ltd. (NASDAQ:RDHL) acquired exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq from Ferring Pharmaceuticals. The agreement has an initial 13-year term and automatic…

RedHill Biopharma divests Talicia to Apotex for $18M upfront

* RedHill Biopharma (RDHL [https://seekingalpha.com/symbol/RDHL]) is divesting [https://seekingalpha.com/pr/20634228-redhill-divests-talicia-to-apotex-for-18-million-cash-upfront-plus-milestones-to-fuel]its Talicia business to a subsidiary…

Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

The inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing disease awareness, and earlier diagnosis. Additionally, the launch of emerging th…

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths -- Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force exper…

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap…

RedHill Biopharma regains Nasdaq stockholders’ equity compliance

* RedHill Biopharma (RDHL [https://seekingalpha.com/symbol/RDHL]) has regained compliance [https://seekingalpha.com/pr/20323207-redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement] with Nasdaq as c…

RedHill received Talicia licensing payments totaling $1.1 million

* RedHill Biopharma (NASDAQ:RDHL [https://seekingalpha.com/symbol/RDHL]) on Monday announced that it has received its first Talicia ex-U.S. sales milestone, royalties and other payments totaling approximately $1.1 million. * Talicia is the…

Form 6K Redhill Biopharma Ltd For: 18 August

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index and the Health C PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…

Gilead’s Quiet Revolution: Is GILD the Next Big Stock to Soar?

Biotechnology company Gilead Sciences (NASDAQ:GILD) wasn’t a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024. Gilead Sciences is doing important scientific wo…

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viability, in a new U.S. Army-funded and cond…

Morning Brew: Bank of America Predicts S&P 500 Upside, Kraft Heinz Approves $3B Buyback

Bank of America's global research team has outlined 10 key investment themes for 2024, forecasting a 10% rise in the S&P 500 (SP500), alongside potential interest rate cuts and Brent oil averaging $90 per barrel. The themes include a globa…

RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.

RedHill's partner, Gaelan Medical, part of the Ghassan Aboud Group (GAG), receives marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia Gaelen placed a meaningful initial Talicia order and commences commerc…

RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

RHB-107 (upamostat) accepted for inclusion in ACESO's PROTECT adaptive platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa The substantial 300-patient Phase 2 study, pr…

RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise

TEL AVIV, ISRAEL, and RALEIGH, N.C., July 25, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced regis…

RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds

TEL AVIV, ISRAEL & RALEIGH, N.C., July 21, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with…

RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development

Opaganib awarded a further $1.7 million in U.S. Government funding for development as a medical countermeasure for gastrointestinal acute radiation syndrome (ARS) The Small Business Innovation Research (SBIR) grant, given to RedHill's deve…

RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights

Q1/23 Talicia net revenues of $3.4 million; Cash balance of $28.8 million as of March 31, 2023[1]; Extinguishment of all debt obligations in exchange for the transfer of rights in Movantik®[2] resulting in net income of $50.2 million for t…

RedHill Provides R&D Update

RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-stage development for outpatient treatm…

RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

TEL AVIV, Israel and RALEIGH, N.C., May 15, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received a written notification (the "N…

RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week

New Talicia PBPK modeling data, published in AP&T Journal, showed that generically substituted regimens are non-bioequivalent to Talicia Separately, new Talicia PBPK modeling data, presented at DDW, supports bioequivalence between TID and…

RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting

European Patent Office grants RHB-102 patent covering antiemetic extended-release solid dosage forms for the prevention of nausea and vomiting (CINV/RINV), providing protection of RHB-102 to March 2034 Discussions with potential commercial…

RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights

Having extinguished all debt and significantly reduced cost-base, RedHill is now focused on late-stage pipeline advancement, in collaboration with U.S. and other governments, commercial growth and revenue-generating product acquisition opp…

Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet

To the annoyance of some shareholders, RedHill Biopharma Ltd. (NASDAQ:RDHL) shares are down a considerable 41% in the last month, which continues a horrid run for the company. The recent drop completes a disastrous twelve months for shareh…

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

TEL AVIV, Israel & RALEIGH, N.C., April 11, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received confirmation from The Nasdaq Stock…

RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering

TEL AVIV, Israel and RALEIGH, N.C., April 3, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced regist…

RedHill Biopharma Announces $6 Million Registered Direct Offering

TEL AVIV, Israel and RALEIGH, N.C., March 30, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement f…

RedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the brunt

Key Insights The considerable ownership by individual investors in RedHill Biopharma indicates that they collectively have a greater say in management and business strategy 50% of the business is held by the top 14 shareholders Using data…

RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders

RedHill commits to reimburse out-of-pocket costs for Talicia patients that complete the full 14-day treatment course and whose infection is not eradicated based on post-treatment confirmation testing - warranty commitment extends to all co…

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

TEL AVIV, Israel and RALEIGH, NC, March 16, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to implement a ratio change of the Co…

RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor

TEL AVIV, Israel and RALEIGH, NC, March 8, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreement, with a single investor, for the issuance…

RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development

RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program The National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation medic…

RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program

The National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation medical countermeasures Product Development Support contract as a potential treatment for…

RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan

RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support UK MHRA scientific advice meeting deems RHB-102 (BEKINDA®) data supportive of submission for approval for…

RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support

UK MHRA scientific advice meeting deems RHB-102 (BEKINDA®) data supportive of submission for approval for chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV) RHB-102 UK Marketing Authorisation Application (MAA) submission…